Taiwan Bio and TRACT Therapeutics have recently announced a strategic partnership aimed at advancing cellular therapy to transform the prevention of allograft rejection in solid organ transplants. The collaborative effort will involve a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States and Taiwan.

The partnership leverages Taiwan Bio's expertise in cellular therapy manufacturing and TRACT Therapeutics' immune modulating regulatory T cell therapy platform. Through this collaboration, the companies aim to explore new frontiers in allogeneic tissue transplant, with a primary focus on improving patient outcomes and enhancing the quality of life. The upcoming Phase 2 trial builds on promising results from a Phase 1 study, which demonstrated excellent safety and encouraging efficacy signals with TRACT's autologous Treg product, TregCelTM.

Cyrus Yang, COO of Taiwan Bio, expressed optimism about the collaboration, stating, "We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options. Together with TRACT Therapeutics, we can bring a synergy of technology and experience to accelerate the development of transformational Treg therapies."

John Flavin, CEO of TRACT Therapeutics, sees the collaboration as a strategic milestone, saying, "Our collaboration with Taiwan Bio is a strategic milestone that paves the way for mutual success. TRACT recognizes the importance of a state-of-the-art GMP cell manufacturing facility to advance the development of our Treg therapy, and we found the best-in-class capabilities of the Taiwan Bio manufacturing team align perfectly with our needs."

Joseph R Leventhal, MD, PhD, Fowler McCormick Professor of Surgery at Northwestern University and Scientific Founder of TRACT Therapeutics, emphasized the critical need for better treatments in organ transplantation. He added, "TRACT’s regulatory T cell therapy platform holds the promise to revolutionize our approach to organ transplantation by not only preventing organ rejection but also enabling us to reduce the reliance on toxic immunosuppressive drugs."

Matthew Cooper, MD, Chief of Transplantation at the Medical College of Wisconsin, highlighted the potential pivotal shift in the field of transplantation, stating, "This therapy represents a potential pivotal shift in the field of transplantation, offering new hope for improved outcomes and enhanced quality of life for all patients receiving solid organ transplants."

The Phase 2 clinical trial marks the first collaborative effort between the two companies, with further updates on the trial's progress expected in the coming months.

 

 

Source: businesswire.com

Report Abuse